GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CEL-SCI Corp (AMEX:CVM) » Definitions » Cyclically Adjusted Price-to-FCF

CEL-SCI (CEL-SCI) Cyclically Adjusted Price-to-FCF : (As of Jun. 08, 2024)


View and export this data going back to 1991. Start your Free Trial

What is CEL-SCI Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


CEL-SCI Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for CEL-SCI's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CEL-SCI Cyclically Adjusted Price-to-FCF Chart

CEL-SCI Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CEL-SCI Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CEL-SCI's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, CEL-SCI's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CEL-SCI's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CEL-SCI's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where CEL-SCI's Cyclically Adjusted Price-to-FCF falls into.



CEL-SCI Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

CEL-SCI's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, CEL-SCI's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.087/131.7762*131.7762
=-0.087

Current CPI (Mar. 2024) = 131.7762.

CEL-SCI Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -2.347 100.560 -3.076
201409 -2.180 100.428 -2.860
201412 -1.862 99.070 -2.477
201503 -2.256 99.621 -2.984
201506 -1.837 100.684 -2.404
201509 -1.381 100.392 -1.813
201512 -1.311 99.792 -1.731
201603 -1.050 100.470 -1.377
201606 -1.094 101.688 -1.418
201609 -1.277 101.861 -1.652
201612 -0.697 101.863 -0.902
201703 -0.408 102.862 -0.523
201706 -0.372 103.349 -0.474
201709 -0.349 104.136 -0.442
201712 -0.225 104.011 -0.285
201803 -0.247 105.290 -0.309
201806 -0.167 106.317 -0.207
201809 -0.175 106.507 -0.217
201812 -0.141 105.998 -0.175
201903 -0.130 107.251 -0.160
201906 -0.142 108.070 -0.173
201909 -0.114 108.329 -0.139
201912 -0.120 108.420 -0.146
202003 -0.126 108.902 -0.152
202006 -0.120 108.767 -0.145
202009 -0.123 109.815 -0.148
202012 -0.180 109.897 -0.216
202103 -0.211 111.754 -0.249
202106 -0.175 114.631 -0.201
202109 -0.121 115.734 -0.138
202112 -0.112 117.630 -0.125
202203 -0.076 121.301 -0.083
202206 -0.136 125.017 -0.143
202209 -0.114 125.227 -0.120
202212 -0.109 125.222 -0.115
202303 -0.174 127.348 -0.180
202306 -0.132 128.729 -0.135
202309 -0.108 129.860 -0.110
202312 -0.102 129.419 -0.104
202403 -0.087 131.776 -0.087

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


CEL-SCI  (AMEX:CVM) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


CEL-SCI Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of CEL-SCI's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


CEL-SCI (CEL-SCI) Business Description

Industry
Traded in Other Exchanges
Address
8229 Boone Boulevard, Suite 802, Vienna, VA, USA, 22182
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The company is focused on activating the immune system to fight cancer and infectious diseases. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
Executives
Gail K Naughton director C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Peter R Young director 8229 BOONE BLVD, STE 802, VIENNA VA 22182
John Cipriano officer: Senior Vice President 8229 BOONE BLVD, SUITE 802, VIENNA VA 22182
Robert Eugene Watson director 245 N. HIGHLAND AVE NE, SUITE 230-296, ATLANTA GA 30307
Bruno Jean-marie Baillavoine director 8229 BOONE BLVD., SUITE 802, VIENNA VA 22182
Eyal Talor officer: Chief Scientific Officer 8229 BOONE BLVD, STE 802, VIENNA VA 22182
Geert R Kersten director, officer: Chief Executive Officer 8229 BOONE BLVD, STE 802, VIENNA VA 22182
Daniel H Zimmerman officer: Sr. Vice President, Research 8229 BOONE BLVD, STE 802, VIENNA VA 22182
Patricia B Prichep officer: Sr. Vice President, Operations 8229 BOONE BLVD., SUITE 802, VIENNA VA 22182
Clara Maximilian De director, officer: President
C Richard Kinsolving director 8229 BOONE BLVD, STE 802, VIENNA VA 22182
Alexander G Esterhazy director 8229 BOONE BLVD, STE 802, VIENNA VA 22182